C1q tumor necrosis factor-related protein 4 is associated with coronary artery disease in patients with type 2 diabetes.
C1q tumor necrosis factor-related protein 4
Coronary artery disease
Type 2 diabetes mellitus
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
revised:
15
05
2022
received:
01
02
2022
accepted:
20
05
2022
pubmed:
23
5
2022
medline:
7
10
2022
entrez:
22
5
2022
Statut:
ppublish
Résumé
To evaluate the correlation of circulating C1q tumor necrosis factor-related protein 4 (CTRP4) with coronary artery disease (CAD) in type 2 diabetes mellitus patients. A total of 240 individuals with type 2 diabetes mellitus were enrolled in our center between January 2020 and December 2020. They were assigned into two groups, including the CAD and non-CAD groups, based on coronary angiography or computed tomography angiography findings. Serum CTRP4 levels were detected by an enzyme-linked immunosorbent assay kit. The association of CTRP4 with CAD was determined by logistic regression analysis. The predictive value of CTRP4 for CAD was calculated by receiver operating characteristic curve analysis. Median serum CTRP4 amounts were markedly elevated in the CAD group in comparison with the non-CAD group (10.37 vs 3.75 ng/mL, P < 0.01). Binary logistic regression showed that CTRP4 was associated with CAD and even the amount of coronary artery lesions (P < 0.05). In receiver operating characteristic curve analysis, the area under the receiver operating characteristic curve was greater for CTRP4 compared with HbA1c or CRP (0.87 vs 0.74, 0.87 vs 0.80, P < 0.01). The area under the curve for CTRP4 and glycated hemoglobin in combination was larger than that obtained for CTRP4 combined with CRP (0.91 vs 0.87, P < 0.01). According to the maximum Youden index criteria, the optimal cut-off of CTRP4 was 5.42 ng/mL, which yielded a sensitivity of 84.4% and a specificity of 76.7% in predicting CAD in type 2 diabetes mellitus patients. Serum CTRP4 levels are positively correlated with CAD occurrence and severity. Combining CTRP4 and glycated hemoglobin has a better predictive value for CAD in type 2 diabetes mellitus patients.
Identifiants
pubmed: 35598316
doi: 10.1111/jdi.13842
pmc: PMC9533036
doi:
Substances chimiques
Biomarkers
0
C1QTNF4 protein, human
0
Cytokines
0
Glycated Hemoglobin A
0
Tumor Necrosis Factors
0
Complement C1q
80295-33-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1723-1731Subventions
Organisme : Clinical Characteristic of Health System in Putuo District, Shanghai
ID : 2020tszk01
Organisme : Shanghai Key Medical Specialities
ID : ZK2019B16
Informations de copyright
© 2022 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Diabetes Metab Syndr. 2019 Mar - Apr;13(2):1449-1455
pubmed: 31336505
Trends Immunol. 2004 Oct;25(10):551-61
pubmed: 15364058
Am J Physiol Endocrinol Metab. 2014 Apr 1;306(7):E779-90
pubmed: 24473438
N Engl J Med. 2007 Jan 18;356(3):213-5
pubmed: 17229948
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10302-7
pubmed: 15231994
Eur J Immunol. 2021 Feb;51(2):380-392
pubmed: 33080044
PLoS One. 2018 Jan 30;13(1):e0192159
pubmed: 29381773
Genes Genomics. 2019 Apr;41(4):397-406
pubmed: 30474828
J Biol Chem. 2014 Feb 14;289(7):4055-69
pubmed: 24366864
Am J Physiol Regul Integr Comp Physiol. 2013 Sep;305(5):R522-33
pubmed: 23842676
J Biol Chem. 2012 Jan 6;287(2):1576-87
pubmed: 22086915
Eur J Epidemiol. 2017 May;32(5):363-375
pubmed: 28397016
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
Lancet. 2005 Apr 9-15;365(9467):1333-46
pubmed: 15823385
J Endocrinol. 2014 Mar 13;221(1):111-9
pubmed: 24492466
Redox Biol. 2019 Jan;20:247-260
pubmed: 30384259
Diabetes Res Clin Pract. 2014 Feb;103(2):137-49
pubmed: 24630390
Int J Environ Res Public Health. 2018 Jan 05;15(1):
pubmed: 29304014
Int J Rheum Dis. 2017 Mar;20(3):287-297
pubmed: 28205331
Diabetologia. 2012 Nov;55(11):2895-905
pubmed: 22890825
Biomed Res Int. 2015;2015:971683
pubmed: 26457306
Endocr J. 2014;61(9):841-7
pubmed: 24965225
Eur Heart J. 2016 Jun 07;37(22):1762-71
pubmed: 26705391
Cardiol Res Pract. 2015;2015:274892
pubmed: 26697259
Kardiol Pol. 2018;76(3):662-668
pubmed: 29297191
Nat Rev Immunol. 2022 Apr;22(4):251-265
pubmed: 34389841
J Cardiovasc Pharmacol. 2018 Oct;72(4):167-175
pubmed: 29979351
J Biol Chem. 2011 May 6;286(18):15652-65
pubmed: 21378161
Atherosclerosis. 2016 Jul;250:38-45
pubmed: 27175610
JAMA. 1979 May 11;241(19):2035-8
pubmed: 430798
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Circulation. 2008 Apr 15;117(15):1945-54
pubmed: 18378618
Cancer Lett. 2011 Sep 28;308(2):203-14
pubmed: 21658842
Neuroscience. 2020 Mar 1;429:1-9
pubmed: 31917347
Cytokine. 2019 Jan;113:326-331
pubmed: 30337217
J Hepatol. 2018 Feb;68(2):335-352
pubmed: 29122390
Diabetes Res Clin Pract. 2010 Sep;89(3):309-19
pubmed: 20493574
Cell Mol Immunol. 2017 Oct;14(10):868-870
pubmed: 29026217
PLoS One. 2016 Dec 29;11(12):e0168773
pubmed: 28033351
Clin Chim Acta. 2022 Jan 1;524:187-191
pubmed: 34801485
FASEB J. 2008 May;22(5):1502-11
pubmed: 18171693
Circ Res. 2014 Jun 6;114(12):1847-51
pubmed: 24824094
Cardiovasc Diabetol. 2016 Oct 13;15(1):147
pubmed: 27733159
Atherosclerosis. 2019 Jul;286:1-6
pubmed: 31051410
Mol Cell Endocrinol. 2016 Jan 5;419:235-43
pubmed: 26523509
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Int J Cardiol. 2017 Feb 1;228:129-136
pubmed: 27863353
J Biol Chem. 2010 Dec 17;285(51):39691-701
pubmed: 20952387
Clin Endocrinol (Oxf). 2014 Dec;81(6):841-6
pubmed: 24612181
Circulation. 2012 Jun 26;125(25):3066-8
pubmed: 22653085
Egypt Heart J. 2020 Sep 29;72(1):66
pubmed: 32990846
Can J Cardiol. 2018 May;34(5):565-574
pubmed: 29731020
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Inflamm Bowel Dis. 2011 Dec;17(12):2462-71
pubmed: 21351204
Lipids Health Dis. 2014 Dec 04;13:181
pubmed: 25477191
Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1084-E1100
pubmed: 33017221
Curr Vasc Pharmacol. 2020;18(2):110-116
pubmed: 30961498
FASEB J. 2009 Jan;23(1):241-58
pubmed: 18787108
J Neuroinflammation. 2021 Jul 18;18(1):159
pubmed: 34275474
Curr Atheroscler Rep. 2020 May 28;22(6):22
pubmed: 32468164
Biochem Biophys Res Commun. 2015 Mar 20;458(4):890-5
pubmed: 25701788
Ther Adv Endocrinol Metab. 2021 Nov 30;12:20420188211059884
pubmed: 34868546
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Nov;32(11):1441-1445
pubmed: 27774931
Cell Mol Immunol. 2016 Sep;13(5):688-99
pubmed: 27086950